What's new?

Added 1 day ago Drug news

FDA advisory committee does not recommend oxycodegol ( NKTR 181) as a treatment for chronic pain and the drug is withdrawn.- Nektar Therapeutics

Nektar Therapeutics issued a statement following a meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and...

Added 1 day ago Drug news

FDA accepts filing of Opdivo + Yervoy combination to treat first-line metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.- BMS

Bristol-Myers Squibb Company announced the FDA has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with...

Added 1 day ago Drug news

Acasti Pharma Inc reports results for TRILOGY 1 phase III trial of CaPre for the treatment of severe hypertriglyceridemia .

Acasti Pharma Inc. a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre (omega-3...

Added 2 days ago Drug news

Abbott to initiate REPAIR MR trial of MitraClip for people with primary mitral regurgitation eligible for open-heart surgery.

Abbott announced that the FDA has approved a first-of-its-kind clinical trial that will compare the effectiveness of Abbott's minimally invasive...

Added 2 days ago Drug news

Phase III trial of Skyrizi meets all endpoints in plaque psoriasis.- AbbVie

Of patients treated with Skyrizi, 87 percent achieved PASI 90 compared to 57 percent of Cosentyx-treated patients at 52 weeks...